Cure8 trial brief
Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical to deliver alongside standard care.
Adult patients with Crohn’s disease or ulcerative colitis interested in self-management tools; clinicians advising on nonpharmacologic support; researchers of digital health and IBD.
This is a registered interventional clinical trial (recruiting) testing a 24-week digital self-management program plus standard care versus standard care alone for adults with active inflammatory bowel disease (Crohn’s disease or ulcerative colitis) and impaired IBD-specific quality of life.
The program is delivered via web or mobile, includes modular self-management content, and participants complete questionnaires and clinician assessments at baseline, 8, 12, and 24 weeks. Primary outcomes are feasibility metrics (recruitment rate, retention, assessment completion) and acceptability via qualitative interviews.
The study plans to enroll about 40 participants at the University of Michigan and targets people with clinically active disease (HBI ≥5 for CD or SCCAI ≥3 for UC) and fecal calprotectin >250 µg/g. Key exclusions include lack of regular internet access and having an ostomy or planned imminent surgery.
This record describes the trial design and feasibility goals; it does not report study results or efficacy findings. If you’re considering participation, the listing notes participants may stop using the program at any time without affecting standard care.
Trial registry entry describing design and feasibility outcomes; no results reported. The study is small (n≈40) and focuses on acceptability and feasibility, not definitive efficacy. Participation requires internet access and excludes people with ostomies or imminent surgery.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
